The patents cover inhaled insulin treatment for diabetes. Detailed terms of the settlement were not disclosed.
The lawsuit was originally filed in August 2006 in US Federal Court in the Southern District of New York. In December 2006, a federal judge in Manhattan denied a request by Novo Nordisk to halt Exubera sales, saying the need for new treatments trumped Novo’s allegations of patent infringement.